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variety of organs and diseases. The intestinal organoids have 
been shown to be a very power tool for the study of Cancer, 
Cystic Fibrosis and Inflammatory Bowel Disease (Dekkers, Nat 
Med 2013; van de Wetering, Cell in press). The models 
represent previously unavailable in vitro models and patient 
specific samples for drug development, patient stratification 
and diagnostics. In addition, we recently showed the 
organoids are amendable to genetic corrections by novel and 
conventional biochemical techniques such as Crispr/Cas9 
(Drost et al., Nature 2015; Schwank et al., Cell Stem Cell 
2013). Finally, the in vitro stability of the organoid was 
demonstrated by the integration after transplantation of 
human liver cells into recipient mice. This makes the 
organoid a unique new platform for drug development, for 
precision medication for patients in the clinic, and a possible 
new source for cell therapy.  
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Following ionizing radiation exposure, double strand DNA 
breaks activate the ataxia telangiectasia mutated (ATM) 
kinase, which then phosphorylates a large number of target 
proteins to orchestrate the DNA damage response. One of the 
key proteins that is activated by ionizing radiation in an ATM-
dependent manner is the tumor suppressor protein p53. Our 
laboratory has utilized the Cre-loxP system to delete ATM, 
p53 or both genes in different cell types in mice. We have 
also employed reversible in vivo shRNA to temporarily inhibit 
p53 during radiation exposure. We find that the roles of ATM 
and p53 in normal tissue radiation response are cell type 
specific. In bone marrow exposed to radiation, p53 acts to 
kill stem and progenitor hematopoietic cells, which increases 
acute hematological toxicity and promotes radiation-induced 
lymphomas. In gastrointestinal epithelial cells, p53 prevents 
the radiation-induced gastrointestinal syndrome. In 
endothelial cells, p53 prevents radiation-induced heart 
disease. Although deletion of ATM in endothelial cells does 
not sensitize mice to radiation-induced cardiac injury, in the 
setting of p53 deletion, ATM further sensitizes mice to 
radiation-induced heart disease. Taken together, these 
studies define cell type specific roles for ATM and p53 in 
mediating normal tissue response to ionizing radiation and 
suggest opportunities for combining radiotherapy with 
inhibitors of the ATM-p53 pathway to improve the 
therapeutic ratio when treating cancers at specific anatomic 
sites. 
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Due to its anatomical localization and high turnover, 
epidermis is a major target for carcinogens, and skin 
carcinoma is one of the most frequent human cancers. 
Ionizing radiation (IR) can induce carcinoma in skin, but the 
respective roles of keratinocyte stem cells and their progeny 
in the carcinogenic process is unclear. We characterized cell 
intrinsic radiosensitivity of keratinocyte stem cells (KSC) to 
gamma rays. Primary KSC were found radioresistant to high 
radiation doses (Rachidi, 2007), as well as to low doses. They 
repair rapidly all types of DNA damage (Harfouche, 2010), 
both after ionizing radiation and UVB exposure (Marie, 
submitted), without going to apoptosis. Activated repair was 
notably due to increased levels of DNA repair proteins and 
activation of nuclear FGF2 signaling. To evaluate the 
potential impact of irradiation on the epigenetic status of 
keratinocyte precursor cells, the Illumina 450K array was 
used, which measures the methylation level of 480,000 
methylation sites (or CpG islands). More than 36 million of 
GpCs have been identified in the human genome, most of 
them located directly in gene sequences or in gene 
promoters. In the present study, analysis of the lists of the 
modified genes obtained by normalized graph-cut DNA-
ranking allowed the definition of: 1) a specific signature of 
long-term alterations after 2 Gy: hundred genes presented 
methylation changes over 3 weeks in culture, with 18 genes 
exhibiting the most discriminant methylation changes at 16 
and 23 days after exposure. Six genes were members of the 
super-family of protocadherins of the alpha type, pointing to 
alterations of cell-cell interactions. 2) a specific signature of 
long-term alterations after 10 mGy: 15 specific genes had 
methylation changes that were discriminant after 16 and 23 
days. From their functions, it appears that the major cell 
responses after 10 mGy were localized at the cell membrane, 
for processes involved in calcium-related cell adhesion, 
signaling, energy status and carcinoma development. As a 
major function of methylation changes is to inhibit 
transcription, these signatures have been validated by 
characterizing the expression of the genes found in the 
signatures. In summary, high and low-dose exposures of 
immature keratinocytes from human epidermis result in 
epigenetic changes, part of them being specific to the dose. 
Methylation changes appear to regulate notably cell functions 
related to cell-cell interactions, cell adhesion and energy 
status.  
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Background: One of the main aims of radiotherapy alone or 
combined with chemo-, immuno- or biologically targeted 
therapy is the maximisation of tumour tissue eradication 
whilst preserving the surrounding normal tissue. This requires 
a deep understanding of the molecular mechanisms of 
radiation sensitivity in order to identify its key players and 
potential therapeutic targets. Currently, a paradigm shift is 
taking place from pure frequentistic association analysis to 
the rather holistic systems biology approach that seeks to 
mathematically model the system to be investigated and to 
allow the prediction of an altered phenotype as the function 
of one single or a signature of biomarkers.  
 
Methods: In the current study cell culture models of 
radiation-resistant tumour cells and normal radiation-
sensitive cells were investigated by multi-level (genome, 
transcriptome, miRNA) omics profiling over time and the 
resulting multi-layer radiation interactome was 
reconstructed. Validation of key network elements in biopsy-
derived multi-omics data from radiotherapy treated HNSCC 
patients was performed and tested for association with 
clinical outcome.  
 
Results: Molecular frameworks including signalling pathways 
senescence, cell cycle, immune system and PI3K/Akt have 
been identified and are therefore likely to drive radiation 
response in tumour and normal cells. Moreover, the 
identified networks could be used to identify molecular key 
players and potential targets for the simultaneous modulation 
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of radiation sensitivity. A subset of these candidate 
molecules could be validated having an impact in clinical 
outcome of radiation therapy treated HNSCC patients.  
 
Conclusion: Our study demonstrates that multi-level 
radiation systems biology allows gaining deeper insights into 
chief mechanisms of radiation sensitivity, thereby paving the 
way for targeted individualised therapy approaches in 
radiation oncology. 
 
Debate: This house believes that progress in the treatment 
of locally advanced NSCLC will come from:  
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A large proportion of non-small cell lung cancer (NSCLC) 
patients are diagnosed with locally advanced (stage III) 
disease. For this patient group the treatment of choice is 
definitive concurrent chemoradiation (CCRT). CCRT results in 
an improved overall survival (OS) compared to sequential 
chemoradiotherapy or radiotherapy alone because of 
improved locoregional control. However 2-year OS rates of 
30-35% are still poor because many patients develop 
locoregional failures (about 30%) and distant metastases 
(about 40%)1. Currently locally advanced NSCLC patients 
selected for CCRT have FDG-PET scanning and imaging of the 
brain (MRI or CT scan). Despite this brain imaging with the 
present chemotherapy regimens used we are faced with the 
problem of brain metastases in about 10% of the patients 
within 1 year after chemoradiation.  
In several chemoradiation studies it was reported that the 
Gross Tumor Volume is correlated with OS. This is rational 
since the tumor volume represents the number of clonogenic 
tumor cells that needs to be eradicated. To improve 
locoregional control the dose prescription could be escalated 
taking into account the individual Gross Tumor Volumes and 
tolerances using image guided adaptive Intensity Modulated 
Radiotherapy (IMRT). However there are radiation oncologists 
who challenge the usefulness of RT dose escalation and 
intensification in patients with stage III NSCLC. The outcome 
of a randomized phase III trial, RTOG 06171, revealed that 
NSCLC patients within the 74 Gy arm given in 7.5 weeks had 
worse local control and significantly worse overall survival as 
compared to the patients treated to 60 Gy arm in 6 weeks2. 
Patients in all study arms received two additional cycles of 
consolidation chemotherapy ± cetuximab. So the obvious 
question is: How do we continue?  
Dose escalation with prolonged overall treatment time in 
NSCLC has previously been proven disappointing because of 
accelerated repopulation3.In an individual patient data meta-
analysis in patients with non-metastatic lung cancer, which 
included trials comparing modified radiotherapy with 
conventional radiotherapy, a significant OS benefit from 
accelerated or hyperfractionated radiotherapy was reported4. 
Another issue is the use of consolidation chemotherapy after 
concurrent chemoradiation. In the RTOG 0617 trial the 
increase in mortality started < 3 months after randomization 
during the period of consolidation paclitaxel-carboplatin 
chemotherapy. Generally taxanes given after RT increases 
toxicity and the combination of high dose to the heart and 
consolidation taxane-based chemotherapy might have caused 
toxic deaths and biased the outcome. RT dose intensification 
while using modern image guided adaptive IMRT and 
accelerated schemes is an important area of ongoing clinical 
research and should not be discontinued.  
In Stereotactic Ablative Body Radiotherapy (SABR) much 
higher biologically equivalent doses are delivered compared 
to conventionally fractionated RT (typically EQD2 of 70-85 
Gy), and has generated outstanding tumor control in early 
stage NSCLC. For SABR a significant dose–response 
relationship was observed for prescription EQD2 of 105 Gy or 
more (2-year LC 96%) or of less than 105 Gy (2-year LC 85%)5. 
Tumor size and overall treatment time were also important 
factors influencing outcome.  
The tumor control probability of SBRT (small tumor volume) 
and conventionally fractionated chemoradiation (large tumor 
volume) were successfully described in a single model6 
suggesting that a dose-response relation in NSCLC does exist.  
Recently there is a growing interest in genetic profiles that 
predict a patient’s response to radiotherapy, because severe 
toxicity in a minority of patients limits the doses that can be 
safely given to the majority. Recent progress in genotyping 
raises the possibility of genome-wide studies. If we know the 
normal tissue reactions to radiotherapy by genotype we will 
really be able to tailor the individual radiation dose.  
In conclusion: Besides the unsolved problem of the 
occurrence of distant metastases there is room for 
improvement of locoregional control in locally advanced 
NSCLC patients treated with chemoradiation. In the era of 
personalized treatment, radiotherapy dose intensification 
using image guided adaptive IMRT could be directed towards 
individual tumor volumes and tolerances. RT dose 
intensification while using accelerated schemes is an 
important area of ongoing clinical research  
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About one third of patients with non-small cell lung cancer 
(NSCLC) present with locoregional disease extension in either 
the mediastinum (T4) or the mediastinal lymph nodes (N2/3). 
Apart from a fraction in which resection after induction 
therapy is sometimes considered, selected patients with 
stage 3 are candidate for a so-called definitive 
radiochemotherapy, administered either sequentially or 
concomitantly. Despite staging with PET-CT scan and 
endosonographic mapping of mediastinal lymph nodes and 
notwithstanding a patient selection for this radical 
treatment, the outcome in stage 3 is nevertheless moderate 
with a median survival of 2 years [1]. Progression occurs after 
a median of 10 months and is due to local relapse or distant 
metastasis in 30 and 45% of cases, respectively. Any advance 
in the outcome in stage 3 NSCLC will hence depend on 
improvements in systemic therapy directed at distant 
metastasis. The past 10 years have seen important changes in 
the paradigm of treatment in selected patients with 
advanced NSCLC, in whom platinum-based doublet 
chemotherapy used to be the standard of care. The discovery 
of drugable genomic alterations has introduced precision 
medicine in oncology. Patients whose NSCLC harbour either 
an activating EGFR mutation, EML-ALK translocation or ROS1 
amplification are now routinely treated with oral small 
molecule kinase inhibitors of the 1st, 2nd and 3rd generation 
instead of chemotherapy, with a significant improvement in 
outcome and a substantial impact on quality of life. Similar, 
although less pronounced effects have been observed when 
adding monoclonal antibodies directed at targets associated 
with angiogenesis or cell growth to the chemotherapy 
backbone. Unfortunately, the incorporation of these 
